MedTrace Logo

Anfibatide Phase Ib-IIa Clinical Trial

NCT01585259 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-07-14

No results posted yet for this study

Summary

Investigate the safety and efficacy of Anfibatide in non-ST segment myocardial infarction patients

Conditions

  • Non-ST Segment Elevation Myocardial Infarction

Interventions

DRUG

Anfibatide

Snake venom

DRUG

Placebo

Saline

Sponsors & Collaborators

  • Lee's Pharmaceutical Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-12-31
Completion
2015-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01585259 on ClinicalTrials.gov